CAM
KERX

Cormorant Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cormorant Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-826,000
Closed -$8.24M – 88
2015
Q2 		$8.24M Hold
826,000
– – 1.1% 29
2015
Q1 		$10.5M Sell
826,000
-174,000
-17% -$2.24M 1.62% 17
2014
Q4 		$14.2M Hold
1,000,000
– – 2.18% 18
2014
Q3 		$13.8M Buy
+1,000,000
New +$15.3M 2.83% 5
2014
Q1 		– Sell
-1,700,000
Closed -$22M – 53
2013
Q4 		$22M Buy
+1,700,000
New +$20.3M 6.39% 3

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Cormorant Asset Management's KERX Position: Q3 2015 in Review

Cormorant Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 826,000 shares — an estimated $8.24M sold.

Cormorant Asset Management first reported a position in KERX in Q4 2013 and held it in 5 quarters. The position peaked at $22M in Q4 2013. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Cormorant Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Cormorant Asset Management sold 826,000 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $8.24M.
  • Cormorant Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 5 quarters.
  • Cormorant Asset Management's Keryx Biopharmaceuticals Inc position peaked at $22M in Q4 2013.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Cormorant Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.